Ipratropium detailed information: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Ipratropium detailed information": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 27: Line 27:
{{CMG}}
{{CMG}}


{{Editor Join}}
 


'''Ipratropium''' (as '''ipratropium [[bromide]]''', trade name '''Atrovent''') is an [[anticholinergic]] drug administered by inhalation for the treatment of [[COPD|obstructive lung disease]]s. It acts by blocking [[muscarinic acetylcholine receptor|muscarinic receptors]] in the lung, inhibiting [[bronchoconstriction]] and [[mucus]] [[secretion]]. It is a non-selective [[muscarinic]] [[antagonist]], and does not diffuse into the blood, which prevents systemic side effects.  Ipratropium is a derivative of [[atropine]]<ref>{{cite journal |author=Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y |title=[Antiallergic asthma effect of ipratropium bromide (Sch 1000) in dogs (author's transl)] |language=Japanese |journal=Nippon Yakurigaku Zasshi |volume=73 |issue=7 |pages=785-91 |year=1977 |pmid=145994}}</ref> but is a quaternary amine and therefore does not cross the [[blood-brain barrier]], which prevents central side effects (anticholinergic syndrome).
'''Ipratropium''' (as '''ipratropium [[bromide]]''', trade name '''Atrovent''') is an [[anticholinergic]] drug administered by inhalation for the treatment of [[COPD|obstructive lung disease]]s. It acts by blocking [[muscarinic acetylcholine receptor|muscarinic receptors]] in the lung, inhibiting [[bronchoconstriction]] and [[mucus]] [[secretion]]. It is a non-selective [[muscarinic]] [[antagonist]], and does not diffuse into the blood, which prevents systemic side effects.  Ipratropium is a derivative of [[atropine]]<ref>{{cite journal |author=Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y |title=[Antiallergic asthma effect of ipratropium bromide (Sch 1000) in dogs (author's transl)] |language=Japanese |journal=Nippon Yakurigaku Zasshi |volume=73 |issue=7 |pages=785-91 |year=1977 |pmid=145994}}</ref> but is a quaternary amine and therefore does not cross the [[blood-brain barrier]], which prevents central side effects (anticholinergic syndrome).

Latest revision as of 16:33, 9 August 2012

Ipratropium detailed information
Clinical data
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Protein binding0 to 9% in vitro
MetabolismHepatic
Elimination half-life2 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H30NO3
Molar mass389.457 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Ipratropium (as ipratropium bromide, trade name Atrovent) is an anticholinergic drug administered by inhalation for the treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a non-selective muscarinic antagonist, and does not diffuse into the blood, which prevents systemic side effects. Ipratropium is a derivative of atropine[1] but is a quaternary amine and therefore does not cross the blood-brain barrier, which prevents central side effects (anticholinergic syndrome).

Ipratropium is also combined with albuterol (salbutamol) (trade names Combivent and Duoneb) for the management of COPD and asthma. Ipratropium is also combined with fenoterol (trade names Duovent and Berodual N) for the management of asthma.

Side effects are as those for other anticholinergics.

Sources

  • Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
  • Boeringer-Ingelheim

Footnotes

  1. ↑ Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y (1977). "[Antiallergic asthma effect of ipratropium bromide (Sch 1000) in dogs (author's transl)]". Nippon Yakurigaku Zasshi (in Japanese). 73 (7): 785–91. PMID 145994.

Template:Asthma and copd rx


de:Ipratropiumbromid


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Ipratropium_detailed_information&oldid=677683"